People with Down syndrome often get Alzheimer’s disease (a type of dementia) when they get older. Dementia is a disease that causes memory loss and other thinking problems. Dementia due to Alzheimer’s occurs when a protein called amyloid builds up in the brain.
The ABATE Study is testing a vaccine for Alzheimer’s.
We want to see if the vaccine is safe. We also want to see if it slows the progression of Alzheimer’s disease in people with Down syndrome.
About 80 people with Down syndrome will take part in the ABATE Study.
The study is being conducted in collaboration with the Alzheimer’s Clinical Trials Consortium – Down Syndrome – ACTC-DS.
Who is eligible for the ABATE Study?
You may be able to join this study if you:
Are between 35 and 50 years old
Your study partner is someone who could support you during your participation. For example, they could be a family member or any relative close to you, or a carer.
If you are interested, please contact your nearest research center to learn more about the ABATE Study and check your eligibility.
Locations
What is the study treatment?
The study treatment, ACI-24.060, is a new vaccine which is not yet on the market. It may help to remove amyloid in the brain. This could slow down memory loss and thinking problems.
In the ABATE Study, you will receive either the vaccine or an inactive vaccine (also called placebo). This is so we can see how the vaccine affects your body. Neither you nor the study team will know which vaccine you are getting.
You will get the vaccine or inactive vaccine, as well as any tests and visits for the study, at no cost.
What happens in the ABATE Study?
The study lasts for about 2 years and is split into 3 parts:
Screening period
The study team will do tests to see if you meet the criteria to join the study. If you can join, you and your study partner will sign consent forms before you begin.
Treatment period
You will get either the vaccine or inactive vaccine 6 times. You will also have visits at the study clinic and phone calls so the study team can check your health and check how the vaccine is working in your body.
Follow-up period
You won’t get the vaccine or inactive vaccine anymore. You will have some visits to check your health and see how the vaccine is working in your body.
Study site location & contact
ABATE is recruiting participants at research centers across the United States, UK and Spain.
To learn more, please contact the nearest study team.
Vanderbilt University Medical Center
Center for Cognitive medecine
1601 23rd Avenue South,
37212, Nashville, Tennessee
University of Kansas Medical Center
Alzheimer’s Disease Research Center
4350 Shawnee Mission Parkway, Suite 1200, 66205, Fairway, Kansas
Barrow Neurological Institute
Alzheimer’s Disease and Memory Disorders Division
240 W Thomas Rd,
Suite 301,
85013, Phoenix, Arizona
Washington University in St. Louis
660 S. Euclid, CB 8111,
63110, St-Louis, Missouri
Massachusetts General Hospital (MGH)
185 Cambridge Street,
Suite 2.222,
02114, Boston, Massachusetts
Indiana University / IU Health
355 W 16th Street, 46202, Indianapolis, Indiana
Biggs Institute for Alzheimer’s and Neurodegenerative Diseases
MC 8070, 7703 Floyd Curl Dr.
78229, San Antonio, Texas
Institute of Psychiatry, Psychology and Neuroscience
16 De Crespigny Park, London, SE5 8AF
Naomi Thomas & Natalie Tanzarella
01223 219789 or 07517 829298
Fulbourn Hospital, Cambridge,CB21 5EF
NIHR Oxford Health Clinical Research Facility
Abigail Stewart & Rachel Delahay
Warneford Lane, Oxford, OX3 7JX
Hospital de la Santa Creu I Sant Pau
Juan Fortea & Isabel Barroeta
C/ Mas casanovas, 90. Bloc A, planta -2 (AGDAC), 08025, Barcelona
Hospital Universitario de la Princesa
Fernando Moldenhauer Diaz
Calle de Diego de León, 62,28006, Madrid
Hospital Universitario Marqués de Valdecilla
Unidad de Deterioro Cognitivo, Servicio de Neurología
Eloy Rodriguez & Andrea Corrales
942 202 520 extensión73650
Av. de Valdecilla, 25,39008, Santander
Hospital Universitario Virgen De Las Nieves
Elizabeth Garcia Penalver
Calle Dr. Azpitarte 4, ( 5ª planta), 18012, Granada